Open Access Peer-reviewed Research Article

Main Article Content

Bailey Krueger
Taylor Frazier
Sheila Galbreath
Tarun Goswami corresponding author

Abstract

The drug release rates of poorly soluble medications such as doxorubicin has been investigated in this paper. Since the drug was fixed, different carriers used to deliver it and their release rates compiled from literature were evaluated in this paper. Even though targeting of drugs is very important in drug delivery, it is not within the scope of this paper. However, functionalization of the carrier may provide this benefit, those constructs are included for comparison in terms of hybrid constructs. Dendrimer, micelles and hybrid constructs used in the delivery of doxorubicin compared in this paper with respect to carrier size and drug loading. Assuming that the dissolution follows a slow release, 40-50% of the drug in the phase I representing a sudden or the burst release, followed by a steady release of 50-60% of the drug in phase II, not all the carriers and their sizes exhibited this behavior. Carriers and hybrid constructs 38nm size were more effective where phases I and II observed, however, as the size decreased to 34 nm or increased above 40nm, minimal release occurred meaning the carriers were too big to penetrate the vasculature permeability. Nano-carriers, dendrimers, micelle, hybrid dendrimers and micelles were found to be effective with the carrier manufacturing, generation, polymer, molecular weight of the carrier and other parameters. The release rate of doxorubicin was found to be effective with dendrimers together with hybrid dendrimer exhibiting a bilinear behavior. Micelles 20nm were more effective representing 60% of release in 10 hours followed by additional 25% in 35 hours exhibiting a bilinear behavior. Size greater than 20nm resulted in slow release reaching less than 10 to 40% of drug. Several drugs exhibited multiple slopes in their kinetics when micelle was used. The therapeutic efficacy of hybrid micelle was superior to other nano-carriers.

Keywords
nano-carriers, dendrimers, micelle, dissolution kinetics, therapeutic efficacy

Article Details

How to Cite
Krueger, B., Frazier, T., Galbreath, S., & Goswami, T. (2022). Therapeutic efficacies of nano carriers in delivering drugs. Journal of Pharmaceutical and Biopharmaceutical Research, 4(2), 296-317. https://doi.org/10.25082/JPBR.2022.02.002

References

  1. Crossen SL and Goswami T. Nanoparticulate carries for drug delivery. Journal of Pharmaceutical and Biopharmaceutical Research, 2022, 4(1): 237-247. https://doi.org/10.25082/JPBR.2022.01.001
  2. Tomalia DA and Fréchet JMJ. Discovery of dendrimers and dendritic polymers: A brief historical perspective. 2002, 40(16): 2719-2728. https://doi.org/10.1002/pola.10301
  3. Vogtle F, Richardt G and Werner N. Dendrimer Chemistry: Concepts, Syntheses, Properties, Applications. 2009. https://doi.org/10.1002/9783527626953
  4. Tomalia D, Christensen J and Boas U. Dendrimers, Dendrons, and Dendritic Polymers: Discovery, Applications, and the Future, Cambridge: Cambridge University Press, 2012. https://doi.org/10.1017/CBO9781139048859
  5. Abbasi E, Aval SF, Akbarzadeh A, et al. Dendrimers: synthesis, applications, and properties. Nanoscale Research Letters, 9(1): 247. https://doi.org/10.1186/1556-276X-9-247
  6. Hawker C, Frechet J and Philippides A. Dendritic molecules and method of production. Patent 5041516, 20 August 1991.
  7. Huhn S. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration inHealthy Volunteers. 17 September 2018. https://www.clinicaltrials.gov
  8. Christensen JB. Delivery of Drugs Volume 2: Expectations and Realities of Multifunctional Drug Delivery Systems. 2020, 29-52. https://doi.org/10.1016/B978-0-12-817776-1.00002-X
  9. Chauhan A, Patil C, Jain P, et al. 14 - Dendrimer-based marketed formulations and miscellaneous applications in cosmetics, veterinary, and agriculture. In Micro and Nano Technologies, Pharmaceutical Applications of Dendrimers, Elsevier, 2020, 325-334. https://doi.org/10.1016/B978-0-12-814527-2.00014-7
  10. Nageli k and Schwender S. The Microscope in Theory and Practice, Palala Press, 2016.
  11. Fox P and Brodkorb A. The casein micelle: Historical aspects, current concepts and significance. International Dairy Journal, 2008, 18(7): 677-684. https://doi.org/10.1016/j.idairyj.2008.03.002
  12. Strick JE. Sparks of life: Darwinism and the victorian debates over spontaneous generation, Harvard University Press, 2002.
  13. McBain JW and Gonick E. Cryoscopic Evidence for Micellar Association in Aqueous Solutions of Non-ionic Detergents.
  14. Zhang Y, Huang Y and Li S. Polymeric micelles: nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech, 2014, 15(4): 862-871. https://doi.org/10.1208/s12249-014-0113-z
  15. Kyung Cho E. A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer, 18 January 2013. https://clinicaltrials.gov
  16. Nippon Kayaku Co., Ltd. A Phase III Study of NK105 in Patients With Breast Cancer, 19 July 2019. https://clinicaltrials.gov
  17. Nippon Kayaku Co., Ltd. A Study of NK012 in Patients With Advanced, Metastatic Triple Negative BreastCancer, 4 August 2009. https://clinicaltrials.gov
  18. Nippon Kayaku Co., Ltd. Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors orNon-Small Cell Lung, Biliary and Bladder Cancer, 15 September 2014. https://clinicaltrials.gov
  19. Nippon Kayaku Co., Ltd. Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone inPancreatic Cancer, 15 April 2020. https://clinicaltrials.gov
  20. Novavax Inc. U.S. Food & Drug. Drug Approval Package: Estrasorb (Estradiol) Topical Emulsion, 9 October 2003. https://www.accessdata.fda.gov
  21. Nippon Kayaku Co., Ltd. Study of NK012 in Patients With Refractory Solid Tumors, 12 October 2007. https://clinicaltrials.gov
  22. SK M. Nanoparticles in modern medicine: state of the art and future challenges. International Journal of Nanomedicine, 2007, 2(2): 129-141. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673971
  23. Varga-Bernal R. Introductory Chapter: Hybrid Nanomaterials, 10 June 2020. https://doi.org/10.5772/intechopen.92012
  24. Dave V, Yadav RB, Kushwaha K, et al. Lipid-polymer hybrid nanoparticles: Development & statistical optimization of norfloxacin for topical drug delivery system. Bioactive Materials, 2017, 2(4): 269-280. https://doi.org/10.1016/j.bioactmat.2017.07.002
  25. Singh B, Saini S, Lohan S, et al. Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes. 2017, 110-148. https://doi.org/10.1016/B978-0-12-809717-5.00003-8
  26. Jain K, Jain NK and Kesharwani P. Dendrimer-Based Nanotherapeutics, 2021, 95-123. https://doi.org/10.1016/B978-0-12-821250-9.00007-X
  27. Gupta U and Perumal O. Chapter 15 - Dendrimers and Its Biomedical Applications, December 2014.
  28. Rana S, Bhattacharjee J, Barick K, et al. Chapter 7 - Interfacial engineering of nanoparticles for cancer therapeutics. In In Micro and Nano Technologies, Nanostructures for Cancer Therapy, 2017. https://doi.org/10.1016/B978-0-323-46144-3.00007-6
  29. Koopaie M. 22 - Nanoparticulate systems for dental drug delivery. In Woodhead Publishing Series in Biomaterials, Nanoengineered Biomaterials for Advanced Drug Delivery, 2020. https://doi.org/10.1016/B978-0-08-102985-5.00022-X
  30. Manne LS. Encyclopedia of Physical Science and Technology (Third Edition), 2003. https://www.sciencedirect.com
  31. Ree BJ, Satoh T and Yamamoto T. Micelle Structure Details and Stabilities of Cyclic Block Copolymer Amphiphile and Its Linear Analogues. Polymers, 2019, 11(1): 163. https://doi.org/10.3390/polym11010163
  32. Mlynarczyk D, Kocki T and Goslinski T. Dendrimer Structure Diversity and Tailorability as a Way to Fight Infectious Diseases, 12 July 2017. https://doi.org/https://doi.org/10.5772/67660
  33. Soares D, Domingues S, Viana D, et al. Polymer-hybrid nanoparticles: Current advances in biomedical applications. Biomedicine & Pharmacotherapy, 2020, 131: 110695. https://doi.org/10.1016/j.biopha.2020.110695
  34. Kurtoglu YE, Mishra MK, Kannan S, et al. Drug release characteristics of PAMAM dendrimer-drug conjugates with different linkers. International Journal of Pharmaceutics, 2010, 384(1-2): 189-194. https://doi.org/10.1016/j.ijpharm.2009.10.017
  35. Tekade RK, Dutta T, Gajbhiye V, et al. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. Journal of Microencapsulation, 2009, 26(4): 287-296. https://doi.org/10.1080/02652040802312572
  36. Zhou DZ, Ma DX, Murphy DCJ, et al. Molecularly Precise Dendrimer-Drug Conjugates with Tunable Drug Release for Cancer Therapy. Angewandte Chemie, 2014, 134(42): 11129-111135. https://doi.org/10.1002/ange.201406442
  37. Hu H, F X and Cao Z. Thermo- and pH-sensitive dendrimer derivatives with a shell of poly(N,N-dimethylaminoethyl methacrylate) and study of their controlled drug release behavior. Polymer, 2005, 46(22): 9514-9522. https://doi.org/10.1016/j.polymer.2005.07.034
  38. Attwood D and D'Emanuele A. Dendrimer-drug interactions. Advanced Drug Delivery Reviews, 2005, 57(15): 2147-2162. https://doi.org/10.1016/j.addr.2005.09.012
  39. Thanh VM, Nguyen TH, Tran TV, et al. Low systemic toxicity nanocarriers fabricated from heparin-mPEG and PAMAM dendrimers for controlled drug release. Materials Science and Engineering: C, 2018, 82: 291-298. https://doi.org/10.1016/j.msec.2017.07.051
  40. Zhang M, Zhu J, Zheng Y, et al. Doxorubicin-Conjugated PAMAM Dendrimers for pH-Responsive Drug Release and Folic Acid-Targeted Cancer Therapy. Pharmaceutics, 2018, 10(3): 162. https://doi.org/10.3390/pharmaceutics10030162
  41. Vembu S, Pazhamalai S and Gopalakrishnan M. Potential antibacterial activity of triazine dendrimer: Synthesis and controllable drug release properties. Bioorganic & Medicinal Chemistry, 2015, 23(15): 4561-4566. https://doi.org/10.1016/j.bmc.2015.06.009
  42. Wang J, He H, Cooper RC, et al. Drug Release via a Self-Cleaving Mechanism. Molecular Pharmaceutics, 2019, 16(5): 1874-1880. https://doi.org/10.1021/acs.molpharmaceut.8b01207
  43. Mehta D, Leong N, Mcleod VM, et al. Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker. Molecular Pharmaceutics, 2018, 15(10): 4568-4576. https://doi.org/10.1021/acs.molpharmaceut.8b00581
  44. Wu SY, Chou HY, Yuh CH, et al. Radiation-Sensitive Dendrimer-Based Drug Delivery System. Advanced Science, 2018, 5(2): 1700339. https://doi.org/10.1002/advs.201700339
  45. Dai XH, Zhang HD and Dong CM. Fabrication, biomolecular binding, in vitro drug release behavior of sugar-installed nanoparticles from star poly($varepsilon$-caprolactone)/glycopolymer biohybrid with a dendrimer core. Polymer, 2009, 500(19): 4626-4634. https://doi.org/10.1016/j.polymer.2009.07.017
  46. Moghimi HR, Zarghi A, Mahboubi A, et al. PAMAM-dendrimer Enhanced Antibacterial Effect of Vancomycin Hydrochloride Against Gram-Negative Bacteria. Journal of Pharmacy & Pharmaceutical Sciences, 2018, 22(1): 10-21. https://doi.org/10.18433/jpps29659
  47. Choi SK, Myc A, Silpe JE, et al. Dendrimer-Based Multivalent Vancomycin Nanoplatform for Targeting the Drug-Resistant Bacterial Surface. ACS Nano, 2013, 7(1): 214-228. https://doi.org/10.1021/nn3038995
  48. Sonawane SJ, Kalhpure RS, Rambharose S, et al. Ultra-small lipid-dendrimer hybrid nanoparticles as a promising strategy for antibiotic delivery: In vitro and in silico studies. International Journal of Pharmaceutics, 2016, 504(1-2): 1-10. https://doi.org/10.1016/j.ijpharm.2016.03.021
  49. Chang Y, Meng X, Zhao Y, et al. Novel water-soluble and pH-responsive anticancer drug nanocarriers: Doxorubicin-PAMAM dendrimer conjugates attached to superparamagnetic iron oxide nanoparticles (IONPs). Journal of Colloid and Interface Science, 2011, 363(1): 403-409. https://doi.org/10.1016/j.jcis.2011.06.086
  50. Golshan M, Salami-Kalajahl M, Roghani-Mamaqani H, et al. Poly(propylene imine) dendrimer-grafted nanocrystalline cellulose: Doxorubicin loading and release behavior. Polymer, 20017, 117: 287-294. https://doi.org/10.1016/j.polymer.2017.04.047
  51. Lee SJ, Jeong YI, Park HK, et al. Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery. International Journal of Nanomedicine, 2015, 10(1): 5489-5503. https://doi.org/10.2147/IJN.S87145
  52. Khutale GV and Casey A. Synthesis and characterization of a multifunctional gold-doxorubicin nanoparticle system for pH triggered intracellular anticancer drug release. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119: 372-380. https://doi.org/10.1016/j.ejpb.2017.07.009
  53. Golshan M, Salami-Kalajahl M, Mirshekarpour M, et al. Synthesis and characterization of poly(propylene imine)-dendrimer-grafted gold nanoparticles as nanocarriers of doxorubicin. Colloids and Surfaces B: Biointerfaces, 2017, 155: 257-265. https://doi.org/10.1016/j.colsurfb.2017.04.029
  54. Zhang M, Guo R, Keri M, et al. Impact of Dendrimer Surface Functional Groups on the Release of Doxorubicin from Dendrimer Carriers. The Journal of Physical Chemistry B, 2014, 118(6): 1696-1706. https://doi.org/10.1021/jp411669k
  55. Hong DW, Lai PL, Ku KL, et al. Biodegradable in situ gel-forming controlled vancomycin delivery system based on a thermosensitive mPEG-PLCPPA hydrogel. Polymer Degradation and Stability, 2013, 98(9): 1578-1585. https://doi.org/10.1016/j.polymdegradstab.2013.06.027
  56. Kim SY, Shin IG, Lee YM, et al. Methoxy poly(ethylene glycol) and $varepsilon$-caprolactone amphiphilic block copolymeric micelle containing indomethacin.: II. Micelle formation and drug release behaviours. Journal of Controlled Release, 1998, 51(1): 13-22. https://doi.org/10.1016/S0168-3659(97)00124-7
  57. Chen W, Zhong P, Meng F, et al. Redox and pH-responsive degradable micelles for dually activated intracellular anticancer drug release. Journal of Controlled Release, 2013, 169(3): 171-179. https://doi.org/10.1016/j.jconrel.2013.01.001
  58. Sun P, Zhou D and Gan Z. Novel reduction-sensitive micelles for triggered intracellular drug release. Journal of Controlled Release, 2011, 155(1): 96-103. https://doi.org/10.1016/j.jconrel.2010.11.005
  59. Chen W, Meng F, Li F, et al. pH-Responsive Biodegradable Micelles Based on Acid-Labile Polycarbonate Hydrophobe: Synthesis and Triggered Drug Release. Biomacromolecules, 2009, 10(7): 1727-1735. https://doi.org/10.1021/bm900074d
  60. Li Q, Yao W, Zhang B, et al. Drug-loaded pH-responsive polymeric micelles: Simulations and experiments of micelle formation, drug loading and drug release. Colloids and Surfaces B: Biointerfaces, 2017, 158: 709-716. https://doi.org/10.1016/j.colsurfb.2017.07.063
  61. Liu H, Farrell S and Uhrich K. Drug release characteristics of unimolecular polymeric micelles. Journal of Controlled Release, 2000, 68(2): 167-174. https://doi.org/10.1016/S0168-3659(00)00247-9
  62. Ponta A and Bae Y. PEG-poly(amino acid) Block Copolymer Micelles for Tunable Drug Release. Pharmaceutical Research, 2010, 27: 2330-2342. https://link.springer.com/article/10.1007/s11095-010-0120-z
  63. Lin J, Zhu J, Chen T, et al. Drug releasing behavior of hybrid micelles containing polypeptide triblock copolymer. Biomaterials, 2009, 30(1): 108-117. https://doi.org/10.1016/j.biomaterials.2008.09.010
  64. Chen W, Meng F, Cheng R, et al. Facile construction of dual-bioresponsive biodegradable micelles with superior extracellular stability and activated intracellular drug release. Journal of Controlled Release, 2015, 210: 125-133. https://doi.org/10.1016/j.jconrel.2015.05.273
  65. Wang W, Sun H, Meng F, et al. Precise control of intracellular drug release and anti-tumor activity of biodegradable micellar drugsvia reduction-sensitive shell-shedding. Soft Matter, 2012, 8: 3949-3956. https://doi.org/10.1039/c2sm07461c
  66. Chen M, Xie S, Wei J, et al. Antibacterial Micelles with Vancomycin-Mediated Targeting and pH/Lipase-Triggered Release of Antibiotics. ACS Applied Materials & Interfaces, 2018, 10(43): 36814-36823. https://doi.org/10.1021/acsami.8b16092
  67. Cong Y, Quan C, Liu M, et al. Alendronate decorated biodegradable polymeric. Journal of Biomaterials Science, Polymer Edition, 2015, 26(11): 629-643. https://doi.org/10.1080/09205063.2015.1053170
  68. Chartpitak T, Tulakarnwong S, Riansuwan K, et al. Vancomycin-impregnated polymer on Schanz pin for prolonged release and antibacterial application. Journal of Drug Delivery Science and Technology, 2018, 47: 223-229. https://doi.org/10.1016/j.jddst.2018.07.016
  69. Jahan F, Zaman SU, Arshad R, et al. Mapping the potential of thiolated pluronic based nanomicelles for the safe. Journal of Drug Delivery Science and Technology, 2021, 61: 102220. https://doi.org/10.1016/j.jddst.2020.102220
  70. Li S, Wu W, Xiu K, et al. Doxorubicin Loaded pH-Responsive Micelles Capable of Rapid Intracellular Drug Release for Potential Tumor Therapy. Journal of Biomedical Nanotechnology, 2014, 10(8): 1480-1489. https://doi.org/10.1166/jbn.2014.1846
  71. Ye YQ, Yang FL, Hu FQ, et al. Core-modified chitosan-based polymeric micelles for controlled release of doxorubicin. International Journal of Pharmaceutics, 2008, 352(1-2): 294-301. https://doi.org/10.1016/j.ijpharm.2007.10.035
  72. Xu C, Song RJ, Lu P, et al. pH-triggered charge-reversal and redox-sensitive drug release polymer micelles co-deliver doxorubicin and triptolide for prostate tumor therapy. International Journal of Nanomedicine, 2018, 13: 7229-7249. https://doi.org/10.2147/IJN.S182197
  73. Sun H, Guo B, Cheng R, et al. Biodegradable micelles with sheddable poly(ethylene glycol) shells for triggered intracellular release of doxorubicin. Biomaterials, 2009, 30(31): 6358-6366. https://doi.org/10.1016/j.biomaterials.2009.07.051
  74. Birhan YS, Darge HF, Hanurry EY, et al. Fabrication of Core Crosslinked Polymeric Micelles as Nanocarriers for Doxorubicin Delivery: Self-Assembly, In Situ Diselenide Metathesis and Redox-Responsive Drug Release. Pharmaceutics, 2020, 12(6): 580. https://doi.org/10.3390/pharmaceutics12060580
  75. Galbreath S, Krueger B, Frazier T, et al. Effectiveness of mesoporous bioglass in drug delivery. Journal of Pharmaceutical and Biopharmaceutical Research, 2022, 4(1): 271-282. https://doi.org/10.25082/JPBR.2022.01.004
  76. Cao D, Zhang X, Akabar M, et al. Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer. Artificial Cells, Nanomedicine, and Biotechnology, 2019, 47(1): 181-191. https://doi.org/10.1080/21691401.2018.1548470
  77. Li M, Tang Z, Lin J, et al. Synergistic Antitumor Effects of Doxorubicin-Loaded Carboxymethyl Cellulose Nanoparticle in Combination with Endostar for Effective Treatment of Non-Small-Cell Lung Cancer. Advanced Healthcare Materials, 2014, 3(11): 1877-1888. https://doi.org/10.1002/adhm.201400108
  78. Prabha G and Raj V. Sodium alginate-polyvinyl alcohol-bovin serum albumin coated Fe3O4 nanoparticles as anticancer drug delivery vehicle: Doxorubicin loading and in vitro release study and cytotoxicity to HepG2 and L02 cells. Materials Science and Engineering: C, 2017, 79: 410-422. https://doi.org/10.1016/j.msec.2017.04.075
  79. Rahman MS, Tahir MA, Noreen S, et al. Osteogenic silver oxide doped mesoporous bioactive glass for controlled release of doxorubicin against bone cancer cell line (MG-63): In vitro and in vivo cytotoxicity evaluation. Ceramics International, 2020, 46(8): 10765-10770. https://doi.org/10.1016/j.ceramint.2020.01.086
  80. Bayda S, Adeel M, Tuccinardi T, et al. The History of Nanoscience and Nanotechnology: From Chemical-Physical Applications to Nanomedicine. Molecules, 2020, 25(1): 112. https://doi.org/10.3390/molecules25010112
  81. Paradise M and Goswami T. Carbon Nanotubes -- Production and Industrial Applications. Materials and Design, 2007, 28(5): 1477-1489. https://doi.org/10.1016/j.matdes.2006.03.008
  82. Brooks Z, Goswami T, Doll A, et al. Transdermal drug dlivery systems: Analysis of adhesion failure. Journal of Pharmaceutical and Biopharmaceutical Research, 2022, 4(1): 2022, 256-270. https://doi.org/10.25082/JPBR.2022.01.003
  83. Assani k, Doll a and Goswami T. Mechanical Properties of nanoparticles in drug delivery kinetics. Journal of Pharmaceutical and Biopharmaceutical Research, 2022, 4(1): 248-255. https://doi.org/10.25082/JPBR.2022.01.002